Amyloidosis - Pipeline Review, H2 2020

July 2020 | 241 pages | ID: AEE243D42A6EN
Global Markets Direct

Abstracts

Amyloidosis - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2020, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.
Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyloidosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 4, 9, 4, 1, 5 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase 0, Preclinical and Discovery stages comprises 1, 1, 1, 1 and 1 molecules, respectively.
Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Amyloidosis - Overview
Amyloidosis - Therapeutics Development
Amyloidosis - Therapeutics Assessment
Amyloidosis - Companies Involved in Therapeutics Development
Amyloidosis - Drug Profiles
Amyloidosis - Dormant Projects
Amyloidosis - Discontinued Products
Amyloidosis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Amyloidosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Amyloidosis - Pipeline by ADRx Inc, H2 2020
Amyloidosis - Pipeline by Akcea Therapeutics Inc, H2 2020
Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H2 2020
Amyloidosis - Pipeline by Amgen Inc, H2 2020
Amyloidosis - Pipeline by Auven Therapeutics Development Switzerland Sarl, H2 2020
Amyloidosis - Pipeline by Bristol-Myers Squibb Co, H2 2020
Amyloidosis - Pipeline by BSIM Therapeutics SA, H2 2020
Amyloidosis - Pipeline by Caelum Biosciences Inc, H2 2020
Amyloidosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020
Amyloidosis - Pipeline by Corino Therapeutics Inc, H2 2020
Amyloidosis - Pipeline by Covalent Bioscience Inc, H2 2020
Amyloidosis - Pipeline by Eidos Therapeutics Inc, H2 2020
Amyloidosis - Pipeline by Johnson & Johnson, H2 2020
Amyloidosis - Pipeline by Mabpharm Ltd, H2 2020
Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2020
Amyloidosis - Pipeline by Oncopeptides AB, H2 2020
Amyloidosis - Pipeline by Precision Biosciences Inc, H2 2020
Amyloidosis - Pipeline by Proclara Biosciences Inc, H2 2020
Amyloidosis - Pipeline by Prothena Corp Plc, H2 2020
Amyloidosis - Pipeline by R Pharm, H2 2020
Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2020
Amyloidosis - Pipeline by Sorrento Therapeutics Inc, H2 2020
Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2020
Amyloidosis - Pipeline by Swedish Orphan Biovitrum AB, H2 2020
Amyloidosis - Pipeline by TheraPharm Deutschland GmbH, H2 2020
Amyloidosis - Pipeline by Vera Therapeutics Inc, H2 2020
Amyloidosis - Dormant Projects, H2 2020
Amyloidosis - Dormant Projects, H2 2020 (Contd..1), H2 2020
Amyloidosis - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Amyloidosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

ADRx Inc
Akcea Therapeutics Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Auven Therapeutics Development Switzerland Sarl
Bristol-Myers Squibb Co
BSIM Therapeutics SA
Caelum Biosciences Inc
Chugai Pharmaceutical Co Ltd
Corino Therapeutics Inc
Covalent Bioscience Inc
Eidos Therapeutics Inc
Johnson & Johnson
Mabpharm Ltd
Neurimmune Holding AG
Oncopeptides AB
Precision Biosciences Inc
Proclara Biosciences Inc
Prothena Corp Plc
R Pharm
Regeneron Pharmaceuticals Inc
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Swedish Orphan Biovitrum AB
TheraPharm Deutschland GmbH
Vera Therapeutics Inc